Universität zu Köln

Hoster, Eva ORCID: 0000-0002-0749-1389, Klapper, Wolfram, Hermine, Olivier ORCID: 0000-0003-2574-3874, Kluin-Nelemans, Hanneke C., Walewski, Jan ORCID: 0000-0003-4247-2674, van Hoof, Achiel, Trneny, Marek ORCID: 0000-0002-6952-6073, Geisler, Christian H., Di Raimondo, Francesco, Szymczyk, Michal, Stilgenbauer, Stephan, Thieblemont, Catherine ORCID: 0000-0002-9941-2448, Hallek, Michael, Forstpointner, Roswitha, Pott, Christiane, Ribrag, Vincent, Doorduijn, Jeanette, Hiddemann, Wolfgang, Dreyling, Martin H. and Unterhalt, Michael (2014). Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. J. Clin. Oncol., 32 (13). S. 1338 - 1347. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Full text not available from this repository.

Abstract

Purpose Mantle-cell lymphoma (MCL) is a distinct B-cell lymphoma associated with poor outcome. In 2008, the MCL International Prognostic Index (MIPI) was developed as the first prognostic stratification tool specifically directed to patients with MCL. External validation was planned to be performed on the cohort of the two recently completed randomized trials of the European MCL Network. Patients and Methods Data of 958 patients with MCL (median age, 65 years; range, 32 to 87 years) treated upfront in the trials MCL Younger or MCL Elderly were pooled to assess the prognostic value of MIPI with respect to overall survival (OS) and time to treatment failure (TTF). Results Five-year OS rates in MIPI low, intermediate, and high-risk groups were 83%, 63%, and 34%, respectively. The hazard ratios for OS of intermediate versus low and high versus intermediate risk patients were 2.1 (95% CI, 1.5 to 2.9) and 2.6 (2.0 to 3.3), respectively. MIPI was similarly prognostic for TTF. All four clinical baseline characteristics constituting the MIPI, age, performance status, lactate dehydrogenase level, and WBC count, were confirmed as independent prognostic factors for OS and TTF. The validity of MIPI was independent of trial cohort and treatment strategy. Conclusion MIPI was prospectively validated in a large MCL patient cohort homogenously treated according to recognized standards. As reflected in current guidelines, MIPI represents a generally applicable prognostic tool to be used in research as well as in clinical routine, and it can help to develop risk-adapted treatment strategies to further improve clinical outcome in MCL.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hoster, Eva UNSPECIFIED orcid.org/0000-0002-0749-1389 UNSPECIFIED Klapper, Wolfram UNSPECIFIED UNSPECIFIED UNSPECIFIED Hermine, Olivier UNSPECIFIED orcid.org/0000-0003-2574-3874 UNSPECIFIED Kluin-Nelemans, Hanneke C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Walewski, Jan UNSPECIFIED orcid.org/0000-0003-4247-2674 UNSPECIFIED van Hoof, Achiel UNSPECIFIED UNSPECIFIED UNSPECIFIED Trneny, Marek UNSPECIFIED orcid.org/0000-0002-6952-6073 UNSPECIFIED Geisler, Christian H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Di Raimondo, Francesco UNSPECIFIED UNSPECIFIED UNSPECIFIED Szymczyk, Michal UNSPECIFIED UNSPECIFIED UNSPECIFIED Stilgenbauer, Stephan UNSPECIFIED UNSPECIFIED UNSPECIFIED Thieblemont, Catherine UNSPECIFIED orcid.org/0000-0002-9941-2448 UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Forstpointner, Roswitha UNSPECIFIED UNSPECIFIED UNSPECIFIED Pott, Christiane UNSPECIFIED UNSPECIFIED UNSPECIFIED Ribrag, Vincent UNSPECIFIED UNSPECIFIED UNSPECIFIED Doorduijn, Jeanette UNSPECIFIED UNSPECIFIED UNSPECIFIED Hiddemann, Wolfgang UNSPECIFIED UNSPECIFIED UNSPECIFIED Dreyling, Martin H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Unterhalt, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-439344
DOI:	10.1200/JCO.2013.52.2466
Journal or Publication Title:	J. Clin. Oncol.
Volume:	32
Number:	13
Page Range:	S. 1338 - 1347
Date:	2014
Publisher:	AMER SOC CLINICAL ONCOLOGY
Place of Publication:	ALEXANDRIA
ISSN:	1527-7755
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language RESPONSE CRITERIA; RITUXIMAB; SURVIVAL; VALIDATION; THERAPY; MIPI; IMMUNOCHEMOTHERAPY; CYCLOPHOSPHAMIDE; TRANSPLANTATION; FLUDARABINE Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/43934